Factors influencing post‐recurrence survival in bladder cancer following radical cystectomy

Study Type – Prognosis (individual cohort)

[1]  L. Kiemeney,et al.  Prognostic factors for survival in patients with recurrence of muscle invasive bladder cancer after treatment with curative intent. , 2011, Clinical genitourinary cancer.

[2]  L. Kiemeney,et al.  1719 PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH RECURRENCE OF MUSCLE INVASIVE BLADDER CANCER AFTER TREATMENT WITH CURATIVE INTENT , 2010 .

[3]  C. Morash,et al.  Surveillance strategies after definitive therapy of invasive bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[4]  D. Penson,et al.  Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. , 2009, The Journal of urology.

[5]  R. Kuefer,et al.  Oncological followup after radical cystectomy for bladder cancer-is there any benefit? , 2009, The Journal of urology.

[6]  C. Dinney,et al.  Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Kavanagh,et al.  Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. , 2007, The Journal of urology.

[8]  R. Hautmann,et al.  Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.

[9]  S. Groshen,et al.  Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. , 2005, The Journal of urology.

[10]  H. Grossman,et al.  Surgical factors influence bladder cancer outcomes: a cooperative group report. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Groshen,et al.  Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. , 2003, The Journal of urology.

[12]  E. Solsona,et al.  Late oncological occurrences following radical cystectomy in patients with bladder cancer. , 2003, European urology.

[13]  F. Burkhard,et al.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Herr.  Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. , 2003, Urology.

[15]  J. Palou,et al.  Upper Tract Transitional Cell Carcinoma Following Cystectomy for Bladder Cancer , 2001, European Urology.

[16]  P. Russo,et al.  Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.

[17]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Bostwick,et al.  Predicting the survival of bladder carcinoma patients treated with radical cystectomy , 2000, Cancer.

[20]  P. Russo,et al.  Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation. , 1999, The Journal of urology.

[21]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Dinney,et al.  The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. , 1996, The Journal of urology.

[23]  Y. Tsuji,et al.  Upper urinary tract involvement after cystectomy and ileal conduit diversion for primary bladder carcinoma. , 1996, European urology.

[24]  M. Pagano,et al.  Survival analysis. , 1996, Nutrition.

[25]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[26]  R. Dodge,et al.  The value of pathologic factors in predicting cancer‐specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate , 1993, Cancer.

[27]  H. Scher.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.

[28]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[30]  W. Zontine.  The urinary bladder. , 1975, Modern veterinary practice.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  V. F. Marshall,et al.  The prognosis with untreated bladder tumors , 1956, Cancer.

[33]  G. J. Thompson,et al.  Multicentric origin of papillary tumors of the urinary tract. , 1951, The Journal of urology.